| 曹航,孟帅,赵珠勋,等.急性冠状动脉综合征早期强化降脂中PCSK9抑制剂的应用现状[J].安徽医药,待发表. |
| 急性冠状动脉综合征早期强化降脂中PCSK9抑制剂的应用现状 |
|
| 投稿时间：2026-08-26 录用日期：2026-11-04 |
| DOI： |
| 中文关键词: 急性冠状动脉综合征 强化降脂 PCSK9抑制剂 低密度脂蛋白胆固醇 早期干预 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 急性冠状动脉综合征(ACS)患者血运重建及他汀治疗后仍存在较高的远期心血管事件风险,其中低密度脂蛋白胆固醇(LDL-C)持续暴露是主要因素之一。ACS早期斑块炎症激活、血栓倾向增加,快速充分降脂至关重要。前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂因强效快速降低LDL-C,已用于ACS早期强化降脂。本文阐述PCSK9抑制剂的作用机制、临床证据及指南推荐,以期为ACS患者血脂管理提供参考。 |
| 英文摘要: |
| Patients with acute coronary syndrome (ACS) still have a high risk of long-term cardiovascular events after revascularization and statin therapy. One of the main factors is the continuous exposure to low-density lipoprotein cholesterol (LDL-C). The activation of plaque inflammation and increased thrombosis tendency in the early stage of ACS make rapid and adequate lipid reduction crucial. The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, due to its potent and rapid ability to lower LDL-C, has been used for early intensive lipid reduction in ACS. This article discusses the mechanism of action, clinical evidence, and guideline recommendations of PCSK9 inhibitors, with the aim of providing a reference for lipid management in ACS patients. |
|
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
